Steroid-Refractory Chronic GVHD Requires More Treatment Options
Corey S. Cutler, MD, MPH, discusses the current treatment options for patients with chronic graft-versus-host-disease and highlighted some upcoming research.
Watch
Results of Phase I Study Reach Primary End Point for mCRPC
Scott T. Tagawa, MD, MS, discusses a phase I dose-escalation study of actinium-225 in patients with progressive metastatic castration-resistant prostate cancer who had previously received at least 1 pathway inhibitor.
Case 4: The Importance of Early Intervention in MPN
Case 4: Assessing Risk for Transformation to AML
Case 4: MPN Transition From Chronic- to Blast-Phase MPN
Case 4: Risk Factors and Genetic Abnormalities of MPN
Case 4: A 68-Year-Old Man With Primary Myelofibrosis
Transformation of Essential Thrombocythemia
Case 3: Risk Assessment of Essential Thrombocythemia
Case 3: Management of Essential Thrombocythemia
Case 3: Low- to Intermediate- Risk Essential Thrombocythemia
Case 3: Prediction of Thrombosis in Essential Thrombocythemia
Case 3: A 39-Year-Old Female With Essential Thrombocythemia
Case 2: Ruxolitinib Treatment for Polycythemia Vera
Case 2: The Diagnosis of Polycythemia Vera
Case 2: The RESPONSE Trial of Ruxolitinib for PV
Case 2: NCCN Guidelines for Treating Polycythemia Vera
Case 2: A 67-Year-Old Male With Polycythemia Vera
Case 1: Initiating Therapy for Myelofibrosis
Case 1: Transformation of Myelofibrosis to AML
Case 1: The Diagnosis of Myelofibrosis
Case 1: Fedratinib Treatment for Myelofibrosis
Case 1: Ruxolitinib Treatment for Myelofibrosis
Case 1: NCCN Guidelines for Treating Myelofibrosis
Case 1: Risk Stratification Models for Myelofibrosis
Case 1: A 68-Year-Old Woman With Primary Myelofibrosis
Myeloproliferative Neoplasms
Experts in myeloproliferative neoplasms review 4 clinical cases and best practices for patients with, primary myelofibrosis, polycythemia vera, essential thrombocythemia, and blast transformation.
Exploring Biomarkers for Immunotherapy Treatment in Lung Cancer
Jamie E. Chaft, MD, discusses biomarkers used to identify patients with lung cancer who would benefit from immunotherapy and the possibility for future biomarkers in this setting.
Liquid Biopsies Become More Common for Gastric and GI Cancers
Joseph Kim, MD, discusses the utility of liquid biopsies in patients with gastric or gastrointestinal cancer at the 2020 GI Cancers Symposium held by the American Society of Clinical Oncology.
Palliative Care Plays Important Role in Advanced Cancers
Kavitha Ramchandran, MD, discusses the role of palliative care for patients with cancer, particularly those with advanced stage disease.